Literature DB >> 21643901

Estrogens and gonadal function in schizophrenia and related psychoses.

Anita Riecher-Rössler1, Jayashri Kulkarni.   

Abstract

Recent research has increasingly pointed to the importance of estrogens and the hypothalamic-pituitary-gonadal axis in schizophrenia. Specifically, there is mounting evidence from clinical, epidemiological, and basic research that estradiol, the main component of estrogens, exerts protective effects in schizophrenia and related psychoses. Possible modes of action of this hormone in the brain have been suggested, and clinical intervention studies have reported the first positive results. Furthermore, there are an increasing number of reports on gonadal dysfunction and states of estrogen deficiency in women with schizophrenia. These findings could have important implications for clinicians and researchers alike.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21643901     DOI: 10.1007/7854_2010_100

Source DB:  PubMed          Journal:  Curr Top Behav Neurosci        ISSN: 1866-3370


  19 in total

Review 1.  The development of psychotic disorders in adolescence: a potential role for hormones.

Authors:  Hanan D Trotman; Carrie W Holtzman; Arthur T Ryan; Daniel I Shapiro; Allison N MacDonald; Sandra M Goulding; Joy L Brasfield; Elaine F Walker
Journal:  Horm Behav       Date:  2013-07       Impact factor: 3.587

Review 2.  Role of estrogen treatment in the management of schizophrenia.

Authors:  Jayashri Kulkarni; Emmy Gavrilidis; Roisin Worsley; Emily Hayes
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

Review 3.  Effects of Sex Steroids in the Human Brain.

Authors:  Tuong-Vi Nguyen; Simon Ducharme; Sherif Karama
Journal:  Mol Neurobiol       Date:  2016-11-08       Impact factor: 5.590

Review 4.  Dendritic spine pathology in schizophrenia.

Authors:  J R Glausier; D A Lewis
Journal:  Neuroscience       Date:  2012-04-27       Impact factor: 3.590

5.  Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial.

Authors:  Judith Usall; Elena Huerta-Ramos; Javier Labad; Jesús Cobo; Christian Núñez; Marta Creus; Gemma García Parés; Daniel Cuadras; José Franco; Eva Miquel; Julio César Reyes; Mercedes Roca
Journal:  Schizophr Bull       Date:  2015-11-20       Impact factor: 9.306

6.  Alterations in dopamine system function across the estrous cycle of the MAM rodent model of schizophrenia.

Authors:  Stephanie M Perez; Li Chen; Daniel J Lodge
Journal:  Psychoneuroendocrinology       Date:  2014-05-14       Impact factor: 4.905

7.  Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age.

Authors:  J Kulkarni; E Gavrilidis; W Wang; R Worsley; P B Fitzgerald; C Gurvich; T Van Rheenen; M Berk; H Burger
Journal:  Mol Psychiatry       Date:  2014-04-15       Impact factor: 15.992

8.  Implications of aneuploidy for stem cell biology and brain therapeutics.

Authors:  Sylvie Devalle; Rafaela C Sartore; Bruna S Paulsen; Helena L Borges; Rodrigo A P Martins; Stevens K Rehen
Journal:  Front Cell Neurosci       Date:  2012-09-05       Impact factor: 5.505

9.  The role of oestrogen and other hormones in the pathophysiology and treatment of schizophrenia.

Authors:  Emily Hayes; Emorfia Gavrilidis; Jayashri Kulkarni
Journal:  Schizophr Res Treatment       Date:  2012-02-19

10.  Gray matter volumetric abnormalities associated with the onset of psychosis.

Authors:  Wi Hoon Jung; Stefan Borgwardt; Paolo Fusar-Poli; Jun Soo Kwon
Journal:  Front Psychiatry       Date:  2012-12-03       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.